Quick method for simultaneously establishing hepatic fibrosis and hyperlipemia double diseases model in rats

Abstract

Abstract: AIM: To establish a relatively simple but reliable rat model of liver fibrosis.Methods: A mixture composed of ethanol (60%)、lard (5 g·kg^-1) and cholesterol(1 g·kg^-1) was supplied in a concentration of 15 ml·kg^-1·d^-1 for one month.Animals are concurrently supplied a normal diet.Results: Biochemical analysis and polarization microscopy combined with image analysis liver sections stained with F3B Sirius red revealed that the whole collagen quantity and type Ⅰ collagen in mixturetreated rat livers were increased very significantly than those of control group.Tissue pathological assay revealed middle to heavy degree cellular swelling and obvious sinus hepaticus hyperaemia in liver.Real time PCR assay showed that type Ⅳ collagen gene expression in model rat liver was very significantly elevated than that of normal rat.The triglyceride contents of liver and blood in model rats were significantly elevated than those of normal control rats.Conclusion: The model provides a convenient method for the production of liver fibrosis and hyperlipemia, and it may be useful for the study of the medicines treating hepatic fibrosis adiposis-hepatca and hyperlipemia.

Key words: hepatic fibrosis, adiposis-hepatica, hyperlipemia, alcohol, collagen

CLC Number:

R965.1

LIU Gui-liang, GAO Li-zhong, LANLAN Xiu-zi, CHEN Ding-ding. Quick method for simultaneously establishing hepatic fibrosis and hyperlipemia double diseases model in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 650-654.

References

1 汪正辉, 王泰龄.酒精性肝病[M].北京:中国医药科技出版社, 2001:50-3
2 李东良, 王玉枚.大鼠酒精性肝损伤模型的建立及病理学观察[J].实用肝脏病杂志, 1998;3:207-8
3 冯志强, 沈志祥, 谭诗云.酒精性脂肪肝的发病机制研究进展[J].世界华人消化杂志, 2002;10:346-8
4 杜施霖, 迟宝荣.酒精性肝损伤动物模型的研究[J].白求恩医科大学学报, 2001;27:682-5
5 Tuskamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, et al.Experimental Liver Cirrhosis induced by alcohol and iron[J].J Clin Invest, 1995;96:620-30
6 Tuskamoto H, Matsuoka M, French S.Experimental models of hepatic fibrosis;A review[J].Semin Liver Dis, 1990;10:56-65
7 Tsukamoto H, Lu SC.Current concepts in the pathogenesis of alcoholic liver injury[J].FASEB J, 2001;15:1335-49
8 Samuel W.Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease[J].J Biomed Sci, 2001;8:20-7
9 David A, Brenner, Tim Waterboer, Sung Kyu Choi, Jeffrey N, Lindquist, et al.Rippe, newaspects of hepatic fibrosis[J].J Hepatol, 2000;32:32-8
10 Scott L.Friedman, molecular regualtion of hepatic fibrosis, an integrated cellular response to tissue injury[J].J Biol Chem, 2000;275:2247-50
11 Frncesco V, Stefano M, Claudio C, Claudio G.Ethanol enhances cholesterol synthesis and secretion in human hepatomal cells [J].Alcolol, 1998;15:299-303
12 Jacob G, Natasha P, Nghi P, Isabelle L, Jing YH, Geoffrey F.Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis[J].J Hepatol, 2003;39:756-64
13 Ion VD, Gavin EA, Peng XJ, Daniell BH, Craig J.McClain, Gene expression in the liver of rats fed alcohol by means of intragastric infusion[J].Alcohol, 2004;33:17-30
14 Amin AN.Role of different dietary fatty acids in the pathogenesis of experimental alcoholic liver disease[J].Alcohol, 2004; 34:21-5
15 Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH.Non-alcoholic steatohepatitis:review of a growing medical problem[J].Eur J InternMed, 2004;15:10-21
16 Wheeler MD, Kono H, YinM, Nakagami M, Uesugit, Arteel GE, et al.The role of Kupffer cell oxidant production in early ethanol-induced liver disease[J].Free Radic Biol Med, 2001; 31:1544-9
17 Maher JJ, Zia S, Tzagarakis C.Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture:studies with rat lipocytes and fibroblasts[J].Alcohol Clin Exp Res, 1994;18:403-9
18 Bataller R, Brenner DA.Liver fibrosis[J].J Clin Invest, 2005;115:209-18
19 Alessandro C.Alcohol-induced fatty liver and inflammation: where do Kupffer cells act[J].J Hepatol, 2000;32;1026-30
20 Chen SZ, Kang H, Ruan QZ.Progress in method for determination of lipid peroxidation[J].J Clin Inspec, 1989;7:98
21 Michael WP.A new mathematical model for relative quantification in real-time RT-PCR[J].Nucleic Acids Res, 2001;29:900

[1]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[2]	CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei. Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248.
[3]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[4]	ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli. Ferroptosis regulatory signaling pathway and its research progress in related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
[5]	SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo. Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
[6]	WU Furong, NING Lijuan, ZHOU Ran. Protective effects of Xiaochaihu Decoction on chemical hepatic fibrosis in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 481-488.
[7]	WU Jiayuan, ZHENG Li, MO Juanfen, GUO Li, CAO Chenxi, BAO Yi. Regulation of N-acetylcysteine on peripheral circulatory and hepatic myeloid-derived suppressor cells in non-alcoholic fatty liver disease mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 989-996.
[8]	LI Hong, LIU Yeqian, GONG Shan, LIU Lin, ZENG Yong, CAI Xiao, WANG Yuhong, REN Weiqiong. Compound Qishao Jiangya tablet reduces blood pressure in mesenteric artery of SHR rats by decreasing the deposition of type Ⅰ and type III collagen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1364-1370.
[9]	CHEN Xi, LING Jiawei, DING Jiaxin, JIANG Zhenzhou, ZHANG Luyong. Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 715-720.
[10]	ZHOU Hongping, YANG Xingxin, ZHUANG Rangxiao, SHAO Yidan, XI Jianjun, LIAO Li, REN Bailu, WANG Pingping, YU Shuying, SHI Tingting. Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 263-270.
[11]	ZENG Xi, HUYANG Liuzi, WU Yamin, CHEN Zhiheng. Protective effect of omega-3 fatty acids on hepatic fibrosis of rats induced by thioacetamide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 892-898.
[12]	YANG Yilin, ZHENG Linying, GU Weiming, PAN Jingqiang, WU Xin，LI Yaojun. Effect of total glucosides of paeony regulate HMGB1, RAGE pathway on nonalcoholic fatty liver disease in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 611-616.
[13]	CHEN Dan, LIN Xiuxian, CHEN Yao. Research on the progress of alcoholic liver disease pathogenesis related to CYP2E1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 198-203.
[14]	LI Xiaoli, SHA Nannan, CHEN Nan, WANG Yongjun, ZHANG Yan. Experimental study progress of smoking- and alcohol-induced osteoporosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1299-1303.
[15]	LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao. Genetic research on the incidence of alcoholic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.